Apricus mulling strategic options after FDA meeting

Share this post

(Reuters) – Drugmaker Apricus Biosciences Inc said on Monday it was considering strategic options after the U.S. Food and Drug Administration told it to develop a new formula for its erectile dysfunction cream Vitaros.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply